What are the unmet needs in the management of myelofibrosis-related anemia?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
What are the unmet needs in the management of myelofibrosis-related anemia?
-
ナレーター：
-
著者：
The MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, What are the unmet needs in the management of myelofibrosis-related anemia?
In this interview, Kiladjian explores the impact and multifactorial causes of myelofibrosis-related anemia, with particular attention to the on-target effects of JAK inhibition. He reviews currently approved JAK inhibitors, emphasizing the anemia benefits seen with momelotinib and pacritinib. Kiladjian also underscores that JAK inhibitors alone do not completely address myelofibrosis-related anemia, highlighting the potential of JAK inhibitor-based combination therapies to address this unmet need.
Hosted on Acast. See acast.com/privacy for more information.